Investor FAQs
101 College Street, Suite 210
New Haven, CT 06510
IRulya Therapeutics is incorporated in Delaware.
The company’s fiscal year-end is December 31.
The company’s common stock trades on the Nasdaq Capital Market under the symbol “IRLA.”
The company does not intend to pay dividends for the foreseeable future.
The company’s transfer agent is Equiniti Trust Company, LLC.
Investors may contact the company’s transfer agent to address questions regarding their stock, such as the transfer of stock, change of address on a shareholder account, or to replace lost stock certificates, through the following ways:
Equiniti Trust Company, LLC
Website: https://equiniti.com/us/ast-access/
Phone: (800) 937-5449 • (718) 921-8124
Mail: EQ • P.O. Box 500 • Newark, New Jersey 07101
The company’s auditor is BDO USA, LLP.
More information about IRulya Therapeutics, including its science and pipeline, can be found on the company’s website at IRulya.com.
The latest corporate news releases and financial reports from IRulya Therapeutics can be found on the Investor section of the company’s website at IRulya.com.
You may visit the Investor section of the company’s website at IRulya.com and locate the company’s SEC filings under Financial Information.
You may make inquiries to ir@IRulya.com.